![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Issues Guidance on Drug Development Tools Qualification Process
FDA Issues Guidance on Drug Development Tools Qualification Process
![FDA_Logo_Blue_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Blue_2016.gif?t=1578316591&width=430)
December 26, 2019
Sponsors voluntarily submitting drug development tools (DDTs), such as biomarkers and clinical outcomes assessments, to the FDA will have to undergo a new qualification process, according to a draft guidance from the agency.
The draft guidance divides DDTs into three buckets: biomarkers, clinical outcomes assessments and animal models. Once the FDA has qualified a DDT, it can be used in future trials without additional reviews.
This guidance replaces a 2014 draft guidance of the same name and follows another draft guidance issued in December 2018 that helps researchers produce valid biomarkers.
Upcoming Events
-
21Oct